Skip to content
Industry
This is research, not advice. We’re not SEBI-registered.

Sai Parenterals share price today

SAIPARENTPharmaConsolidatedPrices to 18 Nov 2026Results to Sep 2026

10Y not available: listed Apr 2026
Price, 200-day average and NIFTY 500Since Apr 2026Since Apr 2026

The price is 1.7% above its 200-day average and 10 points ahead of the NIFTY 500 since listing in Apr 2026

18 Nov 2026₹501.75Since listing in Apr 2026: Sai Parenterals +23.7%, NIFTY 500 +13.8%
₹400₹600May 26Aug 26Nov 26

Price growth

1Y3Y5Y10Y1YToo short3YToo short5YToo short10YToo short

EPS and P/ESince Apr 2026Since Apr 2026

EPS ₹5.35, no figure a year earlier; P/E 93.8

18 Nov 2026₹5.35 EPS
Mar 26
Jun 26
Sep 26
Nov 26
₹0₹6

EPS growth

1Y3Y5Y10Y1YToo short3YToo short5YToo short10YToo short

Revenue and marginsSince Apr 2026Insufficient history, from Mar 2023

Revenue up on a year for 2 quarters in a row; operating margin 20.5%, the highest on this chart

Sep 2026 quarter₹195 crore+261.1% on ₹54 crore a year earlier · NPM 5.6%
Jun 25
Sep 25
Dec 25
Mar 26
Jun 26
Sep 26
0₹300

Revenue: 1Y change, then growth a year; margins are averages

Revenue growth1Y+133.7% to Mar3Y+57.8%/yr to Mar
Rev 5Y, Rev growth10YToo short
OPM average3Y15.8% to Mar5YToo short
NPM average3Y5.2% to Mar5YToo short

Return on capitalInsufficient history, from Mar 2024Insufficient history, from Mar 2024

ROCE was 5.4% for the year to Mar 2026, down from 16.4% in the year to Mar 2024

Year to Mar 20265.4% ROCEInsufficient history: data from Mar 2024
5%15%Sep 24Mar 25Sep 25Mar 26

ROCE average

1Y3Y5Y10Y1Y5.4% to Mar3Y12.9% to Mar5YToo short10YToo short

Profit and cashInsufficient history, from Mar 2023Insufficient history, from Mar 2023

Cash from operations was 208% of profit over 4 years, 664% in the year to Mar 2026

Yearly profit, cash from operations and free cash flow, ₹ crore

FY26₹93 crore operating cashProfit ₹14 crore · Free cash −₹137 crore
FY23
FY24
FY25
FY26
₹100−₹100

Profit growth: 1Y change, then growth a year

1Y3Y5Y10Y1Y0.0% to Mar3Y+51.8%/yr to Mar5YToo short10YToo short

ReinvestmentInsufficient history, from Mar 2023Insufficient history, from Mar 2023

Capex was ₹230 crore in the year to Mar 2026, 13.5 times depreciation

FY26₹230 crore capexWork in progress ₹212 crore
FY23
FY24
FY25
FY26
0₹300

Capex growth: 1Y change, then growth a year

1Y3Y5Y10Y1Y+45,892.0% to Mar3Y+144.5%/yr to Mar5YToo short10YToo short

BorrowingsInsufficient history, from Jun 2025Insufficient history, from Jun 2025

Debt ÷ equity 0.75 at 30 Sep 2026; profit covered interest 1.6x over the last four quarters

Sep 2026 balance sheet0.75 debt ÷ equityNet debt ₹245 crore
Jun 25
Sep 25
Dec 25
Mar 26
Jun 26
Sep 26
06x

Safety

Now3Y ago
Debt ÷ equity0.753Y agon/a
Int. cover1.6x3Y ago2.2x

Operating healthSince Apr 2026Since Apr 2026

Working capital fell from 19 to -161 days since FY23; below zero, customers' advance payments and other dues are larger than the money tied up in the business

Year to Mar 2026-161 days working capital
0200Mar 24Mar 25Mar 26
Working cap.-1611Y−2403Y−1805YToo short
Debtor1731Y−1103Y−585YToo short
Inventory2591Y+603Y+1765YToo short

OwnershipInsufficient history, from Mar 2026Insufficient history, from Mar 2026

FIIs own 2.85%; no figure a year earlier. Promoters hold 51.16%

Share of the company held, %, by quarter end

Sep 2026 quarter2.85% FIIsNo figure a year earlier
20%40%Jun 26Sep 26

FIIs 1Y, FIIs 3Y, Promoters 1Y, Promoters

3Y3YToo short

Sai Parenterals Ltd · SAIPARENT · Pharma - Formulators · price as of the 18 November 2026 close, updated every trading day · results updated weekly · research updated 2 November 2026

Sai Parenterals share price today: ₹501.75 at the close on 18 November 2026. Sai Parenterals (SAIPARENT) is worth ₹2,216 crore and trades at a P/E of 93.8. Latest change: profit up, share price behind the market.

₹501.75Price
93.8×P/E lower than 94% of the last 7 months
₹195 CrRevenue (Sep 2026) +261.1% on a year ago
₹11.0 CrProfit (Sep 2026) +83.3% on a year ago
20.5%Operating margin +0.1 points on a year ago
5.4%ROCE year to Mar 2026

Sai Parenterals Ltd's results are improving, while its P/E is near the low end of its own history over 7 months, higher than only 6% of past readings.

Biggest thing to watch: the price has already been rising for 31 weeks, so timing is the risk more than the business.

The price has been rising for 31 weeks, and the P/E is lower than 94% of its own last 7 months. Over the last four quarters, results have been improving, with profit +83.3% on a year earlier, and 267% of the last 3 years' profit came in as cash. What will decide it: the next one or two quarters of results.

Left out of this page: Its two data sources disagree by up to 141% on reported income across 4 comparable periods, so nothing from the second source is shown here. That is why the yearly return-on-capital-used (ROIC) line and the F-score and the return-on-capital-used (ROIC) reading are missing. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data.

What is the Sai Parenterals share price today?

Sai Parenterals Ltd's share price was ₹501.75 at the close on 18 November 2026. It has been rising for 31 weeks. That is 1.7% above its average price over the last 200 trading days. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 4 weeks running.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Sai Parenterals Ltd is in stage 2. The phase helps read everything below.

Since its first close in our records, on 17 April 2026, it has traded between ₹452 and ₹624, and at that close it sat 29% of the way up from that low.

Week by week since 2026: did it beat the NIFTY 500 over the past 13 weeks?

Ahead in 8 of 25 weeks

Week by week since 2026: did it beat the NIFTY 500 over the past 13 weeks?
Week13-week return vs NIFTY 500
17 Apr 2026no NIFTY 500 reading
24 Apr 2026no NIFTY 500 reading
30 Apr 2026no NIFTY 500 reading
8 May 2026no NIFTY 500 reading
15 May 2026no NIFTY 500 reading
22 May 2026no NIFTY 500 reading
29 May 2026no NIFTY 500 reading
4 Jun 2026no NIFTY 500 reading
5 Jun 2026no NIFTY 500 reading
10 Jun 2026no NIFTY 500 reading
12 Jun 2026no NIFTY 500 reading
17 Jun 2026no NIFTY 500 reading
19 Jun 2026no NIFTY 500 reading
24 Jun 2026+21.8%
25 Jun 2026+18.3%
1 Jul 2026+23.2%
3 Jul 2026+25.5%
10 Jul 2026+18.6%
17 Jul 2026+11.2%
24 Jul 2026+9.1%
31 Jul 2026−4.7%
7 Aug 2026−1.1%
14 Aug 2026−4.2%
21 Aug 2026−9.1%
28 Aug 2026−10.5%
4 Sep 2026−12.9%
11 Sep 2026−10.2%
18 Sep 2026−11.6%
25 Sep 2026−14.7%
1 Oct 2026−9.2%
9 Oct 2026−9.7%
16 Oct 2026−7.8%
23 Oct 2026−7.3%
30 Oct 2026+2.0%
6 Nov 2026−17.1%
8 Nov 2026−11.8%
13 Nov 2026−9.0%
18 Nov 2026−4.6%
Each bar is one week, from 2026 to now (25 weeks with a reading). Green means the stock's return over the previous 13 weeks beat the NIFTY 500; red means it trailed. The colour is strongest at a gap of 25 percentage points or more. A gap means there is no reading for that week.

Over the last 7 months the share price moved +5% while the NIFTY 500 moved +4%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 30 October 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

What changed at Sai Parenterals this quarter?

What are Sai Parenterals' latest quarterly results?

For July to September 2026 (the quarter ended 30 September 2026), Sai Parenterals reported revenue of ₹195 crore, up 261.1% from ₹54.0 crore a year earlier, and a profit of ₹11.0 crore, up 83.3% from ₹6.00 crore.

Sai Parenterals results: July to September 2026 against a year earlier

Sai Parenterals results: July to September 2026 against a year earlier
MeasureJuly to September 2026July to September 2025Change
Revenue₹195 crore₹54.0 crore+261.1%
Profit₹11.0 crore₹6.00 crore+83.3%
Earnings per share₹2.38₹1.72+38.4%
Operating margin20.5%20.4%+0.1 points

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Sai Parenterals' management discussed these results on a call held on 2 November 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

What is the Sai Parenterals share price history?

Sai Parenterals closed at ₹501.75 on 18 November 2026. Its highest weekly close since April 2026 was ₹618.60 on 3 July 2026.

Sai Parenterals share price: then and now

Sai Parenterals share price: then and now
WhenCloseChange to 18 Nov 2026
1 week ago · 11 Nov 2026₹505.95−0.8%
1 month ago · 19 Oct 2026₹483.00+3.9%
6 months ago · 15 May 2026₹481.25+4.3%
Earliest weekly close in our records · 17 Apr 2026₹480.10+4.5%
Highest weekly close since April 2026 · 3 Jul 2026₹618.60−18.9%
Lowest weekly close since April 2026 · 23 Oct 2026₹461.70+8.7%

Weekly closing prices. Each change is the move from that price to the 18 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

38 weekly closes from 17 April 2026 to 18 November 2026.

What is the latest news on Sai Parenterals?

18 Nov 2026: Sai Parenterals closed at ₹501.75, down 0.8% on the week and up 3.9% on the month. 2 Nov 2026: Sai Parenterals held its results call for July to September 2026. Management guided: FY27 full-year revenue to very comfortably cross ₹750 crore.

Earlier

  • Results for July to September 2026: Revenue up 261.1% and profit up 83.3% on a year earlier.

What dividend does Sai Parenterals pay?

Sai Parenterals has paid no dividend on the exchange since its first close in our records (17 April 2026), the start of the period we checked.

No. Sai Parenterals Ltd paid out 0% of its profit as dividends in each of its last 4 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate.

From the exchange corporate-actions record, read 18 November 2026.

What did Sai Parenterals management say on the latest results call?

On the call for July to September 2026, held on 2 November 2026, Sai Parenterals' management guided: FY27 full-year revenue to very comfortably cross ₹750 crore.

“These will be the two big additions for the next two quarters, and as I promised you revenue of 750 crore, I think we will be very comfortably crossing that. On the margin side, the 17% that I promised should be comfortably exceeded.”Anil, Chairman and Managing Director, on the call for July to September 2026

What management guided

  • FY27 full-year operating margin to comfortably exceed around 17%.
  • Gross margin to stay above 45% in all coming quarters on tighter controls.
  • Bhongir new block from Dec 2026 ramping from January to March 2027 and Adelaide commissioning Jan 2027 with TGA Q2CY27 and commercial thereafter.
  • Saicriti completion Jul 2027 with accreditation in about 12 months, exports from FY28 and Europe from FY29.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for July to September 2026, 2 November 2026.

What to watch in Sai Parenterals' next results?

When Sai Parenterals reports October to December 2026, these are the 2 checks that show whether the story is still on course. First: Bhongir block ramp to Australia and New Zealand from flagged start - check delivery flow and in-house tablet support in flagged quarter.

Management raised each of these on the latest results call.

  • Bhongir block ramp to Australia and New Zealand from flagged start - check delivery flow and in-house tablet support in flagged quarter.
  • Adelaide commissioning to TGA clearance to commercial supply - check license outcome and inventory easing toward flagged months.

Which stock lists is Sai Parenterals on?

Sai Parenterals is on one of our India lists: Pharma stocks.

Is Sai Parenterals profitable?

Sai Parenterals Ltd earned ₹11.0 Cr of net profit in the Sep 2026 quarter, +83.3% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY26 profit was ₹14.0 Cr. Over 3 years profit has grown 51.8% a year on average. The same quarter a year earlier earned ₹6.0 Cr.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The Sep 2026 quarter's profit is 5.6% of that quarter's revenue.

For the full year, FY26 profit was ₹14.0 Cr (+0.0% on the year before).

How much revenue does Sai Parenterals make, and is it growing?

Sai Parenterals Ltd reported ₹195 Cr of revenue in the Sep 2026 quarter, +261.1% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 3 years it has grown 57.8% a year on average. The last full year, FY26, came in at ₹381 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹668 Cr.

FY26 revenue was ₹381 Cr, +133.7% on the year before.

Recent pace: the last four quarters grew +351.8% on average, against 57.8% a year over the longer run, so this year is growing faster than its own long-run rate.

How much of every ₹100 of sales does Sai Parenterals keep?

Sai Parenterals Ltd's operating margin was 20.5% in the Sep 2026 quarter, 0.1 percentage points higher than the same quarter a year ago. Across 4 years it has been between 10.2% and 23.9%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed −0.7 percentage points on the year while gross margin changed +12.1 points. So the drop came mostly from the gross margin, which means input costs and prices charged.

Is Sai Parenterals' profit turning into cash?

Over the last 3 years, 267% of Sai Parenterals Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹93.0 Cr of operating cash against ₹14.0 Cr of profit.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

After ₹230 Cr of spending on assets, free cash was −₹137 Cr: it spent more than its operations brought in.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 267% of profit came in as cash: the cash cycle got 34 days longer between FY23 and FY26, so more of each rupee of profit waits in the business before it arrives.

What to look at next: the bigger use of cash is spending on new assets, at 6.9× depreciation over three years. The next section checks what that spending is building.

Where does Sai Parenterals' cash go?

Sai Parenterals Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 208 days in FY26, up from 174 days in FY23. It spent ₹234 Cr on assets over the last 3 years. Customers take 173 days to pay, and stock sits for 259 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹381 Cr, each day of that cycle ties up about ₹1.0 Cr, so roughly ₹217 Cr is tied up in the business at any time.

FY26: customers took 173 days to pay and stock sat for 259 days, about 8.5 months of sales sitting as stock, for a full cycle of 208 days, longer than FY23's 174.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 259 days. Customers pay about 173 days after that. Suppliers are paid at 224 days. Together that makes the 208-day cycle.

Spending on assets: ₹234 Cr over the last 3 years, against ₹34.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹212 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

What is Sai Parenterals' P/E ratio, and how does it compare with its own history?

Sai Parenterals Ltd's P/E is 93.8×, near the low end of its own history: it has been lower only 6% of the time. Its usual P/E (the middle reading) is 145.6×, over 7 months of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹5.35.

93.8×P/E · lower than 94% of its last 7 months

In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple.

Is the Sai Parenterals business getting better or worse?

Sai Parenterals Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

FallingROCE · latest (year to Mar 2026) 5.4%, range 5.0% to 17.0%

Why it matters: with too little history, we say so rather than guess a direction.

One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result.

The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone.

There are fewer than eight usable quarters, so this page does not guess a direction from so little history.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Compound annual growth rate (%)
Measure1yr3yr5yr10yr
Revenue+133.7%+57.8%——
Profit+0.0%+51.8%——
EPS−40.5%+1.8%——
+261.1%Revenue growth (Sep 2026) · latest quarter against a year ago
+83.3%Profit growth (Sep 2026) · latest quarter against a year ago
57.8%Revenue, 3 years · yearly growth over the long run

How much does Sai Parenterals earn on its capital?

Sai Parenterals Ltd earned a ROCE of 5% in FY26. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a 3.7% net margin and 0.27× asset turnover (sales divided by assets).

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

Why the return is what it is (FY26): a 3.7% net margin × 0.27× asset turnover × 2.90× leverage (assets divided by equity) ≈ 2.9% on equity. The margin does its share; borrowing is a big part of it.

The quarterly return lines and the return-on-capital-used (ROIC) line, which only the second data source has, are not shown on this page: its two data sources disagree by up to 141% on reported income across 4 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data.

Does Sai Parenterals have too much debt?

Sai Parenterals Ltd had ₹469 Cr of borrowings against ₹491 Cr of equity in FY26, so its debt is 0.96× its equity. Its operating profit is 2 times its interest bill. Over 3 years borrowings went from ₹69.0 Cr to ₹469 Cr. Over the last 3 of those years it spent ₹234 Cr on assets.

Debt-to-equity shows how much of the business is paid for with borrowed money. Interest cover shows how many times operating profit pays the interest bill. Low debt and high cover are the safe combination.

Part of the spending on assets is being paid for with borrowed money.

What is the Sai Parenterals shareholding pattern?

No group of Sai Parenterals Ltd's owners changed its stake by a full percentage point over the last 4 quarters. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

How far is Sai Parenterals from balance-sheet trouble?

For Sai Parenterals Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

How does Sai Parenterals rank in its industry?

38.3 out of 100, rank 44 of 44 in Pharma - Formulators, with 36% of the evidence available. It is provisional, so it is ranked below companies with full evidence.

Sai Parenterals Ltd scores 38.3 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 44. Some evidence is missing, so the score is pulled toward the middle on purpose.

The three scored parts add up to the total exactly: 17.4 + 9.9 + 11 = 38.3 (no relative-strength reading this week; its 20 points are shared across the other three). This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Which companies is Sai Parenterals compared with?

Sai Parenterals ranks 44 of 44 Pharma - Formulators companies on the 4-Factor Sector Score, with 38.3 out of 100.

  1. 1Marksans Pharma LtdMARKSANS · losing its lead · Most evidence points up · 78% evidence75.8out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 30.5/35 · Revenue 24.2% · Profit 60.3% · Operating margin change 3 points · 100% evidenceCapital efficiency 18.0/25 · ROCE 18.8% (year to Mar 2026) · Operating margin 22.8% · 100% evidenceValuation 15.4/20 · P/E 23.8× · PEG 0.92 · 65% evidenceRelative strength 11.9/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 31.3% · 1 year 53.6% · 25% evidence · 11 of 12 weeks aheadExact sum: 30.5 + 18 + 15.4 + 11.9 = 75.8 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks.
  2. 2Emcure Pharmaceuticals LtdEMCURE · leader · Most evidence points up · 75% evidence72.8out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 26.1/35 · Revenue 21.1% · Profit 33.3% · Operating margin change 0 points · 95% evidenceCapital efficiency 18.0/25 · ROCE 24% (year to Mar 2026) · Operating margin 20.9% · 76% evidenceValuation 10.0/20 · P/E 40.5× · PEG — · 15% evidenceRelative strength 18.7/20 · Strength vs its industry (price vs its 52-week average, weekly) 17.5% · Strength vs NIFTY 500 (same reading) 33.7% · 1 year 72.4% · 100% evidence · 10 of 12 weeks aheadExact sum: 26.1 + 18 + 10 + 18.7 = 72.8 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks.
  3. 3Kwality Pharmaceuticals LtdKPL · breaking out · Most evidence points up · 75% evidence68.3out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 32.5/35 · Revenue 47.6% · Profit 95.9% · Operating margin change 4 points · 100% evidenceCapital efficiency 17.0/25 · ROCE 24.1% (year to Mar 2026) · Operating margin 27.6% · 100% evidenceValuation 6.5/20 · P/E 45.5× · PEG — · 50% evidenceRelative strength 12.3/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 68.2% · 1 year 345.7% · 25% evidence · 9 of 9 weeks aheadExact sum: 32.5 + 17 + 6.5 + 12.3 = 68.3 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks.
  4. 4Rubicon Research LtdRUBICON · losing its lead · Most evidence points up · 87% evidence67.4out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 24.0/35 · Revenue 46.3% · Profit 90.1% · Operating margin change 2 points · 100% evidenceCapital efficiency 18.8/25 · ROCE 28.4% (year to Mar 2026) · Operating margin 25% · 100% evidenceValuation 8.1/20 · P/E 84.3× · PEG 2.11 · 65% evidenceRelative strength 16.5/20 · Strength vs its industry (price vs its 52-week average, weekly) 28.5% · Strength vs NIFTY 500 (same reading) 42.3% · 1 year 144.6% · 70% evidence · 10 of 12 weeks aheadExact sum: 24 + 18.8 + 8.1 + 16.5 = 67.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks.
  5. 5Accent Microcell LtdACCENTMIC · losing its lead · Most evidence points up · 65% evidence66.2out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 21.8/35 · Revenue — · Profit — · Operating margin change 7 points · 27% evidenceCapital efficiency 21.6/25 · ROCE 24.9% (year to Mar 2026) · Operating margin 23.4% · 100% evidenceValuation 10.1/20 · P/E 25.6× · PEG — · 50% evidenceRelative strength 12.7/20 · Strength vs its industry (price vs its 52-week average, weekly) 13.6% · Strength vs NIFTY 500 (same reading) 27.2% · 1 year 97.1% · 100% evidence · 11 of 12 weeks aheadExact sum: 21.8 + 21.6 + 10.1 + 12.7 = 66.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  6. 6Ajanta Pharma LtdAJANTPHARM · quiet · Most evidence points up · 100% evidence65.7out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 30.3/35 · Revenue 25% · Profit 29.8% · Operating margin change 7 points · 100% evidenceCapital efficiency 21.1/25 · ROCE 34.5% (year to Mar 2026) · Operating margin 30.6% · 100% evidenceValuation 9.2/20 · P/E 32.4× · PEG 1.91 · 100% evidenceRelative strength 5.1/20 · Strength vs its industry (price vs its 52-week average, weekly) -10.2% · Strength vs NIFTY 500 (same reading) 2.4% · 1 year 31.7% · 100% evidence · 8 of 12 weeks aheadExact sum: 30.3 + 21.1 + 9.2 + 5.1 = 65.7 · What this means: Earnings are strong; relative strength in its sector is -10.2% and the one-year return is 31.7%.
  7. 7Mankind Pharma LtdMANKIND · turning · Most evidence points up · 100% evidence65.3out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 26.3/35 · Revenue 13.5% · Profit 27.5% · Operating margin change 2 points · 100% evidenceCapital efficiency 15.8/25 · ROCE 13.5% (year to Mar 2026) · Operating margin 27% · 100% evidenceValuation 10.4/20 · P/E 48.3× · PEG 2.64 · 100% evidenceRelative strength 12.8/20 · Strength vs its industry (price vs its 52-week average, weekly) -3.4% · Strength vs NIFTY 500 (same reading) 10.8% · 1 year 17.1% · 100% evidence · 4 of 12 weeks aheadExact sum: 26.3 + 15.8 + 10.4 + 12.8 = 65.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  8. 8Bliss GVS Pharma LtdBLISSGVS · leader · Most evidence points up · 82% evidence65.3out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 30.2/35 · Revenue 25% · Profit 43.1% · Operating margin change 8 points · 95% evidenceCapital efficiency 14.5/25 · ROCE 16.9% (year to Mar 2026) · Operating margin 25.9% · 76% evidenceValuation 6.5/20 · P/E 44.8× · PEG — · 50% evidenceRelative strength 14.1/20 · Strength vs its industry (price vs its 52-week average, weekly) 55.9% · Strength vs NIFTY 500 (same reading) 69.5% · 1 year 325.8% · 100% evidence · 12 of 12 weeks aheadExact sum: 30.2 + 14.5 + 6.5 + 14.1 = 65.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  9. 9Alembic Pharmaceuticals LtdAPLLTD · leader · Evidence leans up · 85% evidence64.0out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 25.8/35 · Revenue 19.7% · Profit 32.7% · Operating margin change 5 points · 100% evidenceCapital efficiency 12.1/25 · ROCE 12.6% (year to Mar 2026) · Operating margin 21.6% · 100% evidenceValuation 14.5/20 · P/E 24.3× · PEG 1.28 · 100% evidenceRelative strength 11.6/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 24.7% · 1 year 15.9% · 25% evidence · 9 of 12 weeks aheadExact sum: 25.8 + 12.1 + 14.5 + 11.6 = 64 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  10. 10Ipca Laboratories LtdIPCALAB · leader · Evidence leans up · 82% evidence62.4out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 24.5/35 · Revenue 12% · Profit 73.8% · Operating margin change 2 points · 95% evidenceCapital efficiency 15.7/25 · ROCE 17% (year to Mar 2026) · Operating margin 23.1% · 76% evidenceValuation 11.7/20 · P/E 33.5× · PEG — · 50% evidenceRelative strength 10.5/20 · Strength vs its industry (price vs its 52-week average, weekly) -3.6% · Strength vs NIFTY 500 (same reading) 9.9% · 1 year 28.4% · 100% evidence · 11 of 12 weeks aheadExact sum: 24.5 + 15.7 + 11.7 + 10.5 = 62.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  11. 11Fredun Pharmaceuticals LtdFREDUN · losing its lead · Evidence leans up · 70% evidence61.2out of 100GrowthCapitalValuationRelative
  12. 12FDC LtdFDC · turning · Evidence leans up · 75% evidence59.2out of 100GrowthCapitalValuationRelative
  13. 13Aurobindo Pharma LtdAUROPHARMA · leader · Evidence leans up · 100% evidence58.9out of 100GrowthCapitalValuationRelative
  14. 14Corona Remedies LtdCORONA · breaking out · Evidence leans up · 73% evidence58.3out of 100GrowthCapitalValuationRelative
  15. 15Lupin LtdLUPIN · quiet · Evidence leans up · 90% evidence57.2out of 100GrowthCapitalValuationRelative
  16. 16Gufic BioSciences LtdGUFICBIO · leader · Evidence leans up · 75% evidence56.8out of 100GrowthCapitalValuationRelative
  17. 17ERIS Lifesciences LtdERIS · basing · Evidence leans up · 67% evidence56.0out of 100GrowthCapitalValuationRelative
  18. 18Kilitch Drugs (India) LtdKILITCH · turning · Evidence leans up · 82% evidence55.8out of 100GrowthCapitalValuationRelative
  19. 19Caplin Point Laboratories LtdCAPLIPOINT · quiet · Evidence leans up · 90% evidence55.2out of 100GrowthCapitalValuationRelative
  20. 20Wockhardt LtdWOCKPHARMA · losing its lead · Evidence leans up · 83% evidence54.7out of 100GrowthCapitalValuationRelative
  21. 21Influx Healthtech LtdINFLUX · quiet · Evidence leans up · 63% evidence54.3out of 100GrowthCapitalValuationRelative
  22. 22Amrutanjan Health Care LtdAMRUTANJAN · breaking out · Evidence leans up · 90% evidence54.1out of 100GrowthCapitalValuationRelative
  23. 23Akums Drugs & Pharmaceuticals LtdAKUMS · losing its lead · Evidence leans up · 75% evidence53.3out of 100GrowthCapitalValuationRelative
  24. 24Strides Pharma Science LtdSTAR · breaking out · Evidence leans up · 82% evidence52.3out of 100GrowthCapitalValuationRelative
  25. 25Zydus Lifesciences LtdZYDUSLIFE · breaking out · Evidence leans up · 90% evidence51.5out of 100GrowthCapitalValuationRelative
  26. 26Glenmark Pharmaceuticals LtdGLENMARK · breaking out · Evidence leans up · 90% evidence50.6out of 100GrowthCapitalValuationRelative
  27. 27Bafna Pharmaceuticals LtdBAFNAPH · breaking out · Evidence leans down · 68% evidence49.1out of 100GrowthCapitalValuationRelative
  28. 28Alkem Laboratories LtdALKEM · quiet · Evidence leans down · 82% evidence48.3out of 100GrowthCapitalValuationRelative
  29. 29J B Chemicals & Pharmaceuticals LtdJBCHEPHARM · Too little evidence to rank firmly · 59% evidence45.8out of 100GrowthCapitalValuationRelative
  30. 30Bharat Parenterals LtdBPLPHARMA · breaking out · Too little evidence to rank firmly · 52% evidence45.8out of 100GrowthCapitalValuationRelative
  31. 31Zim Laboratories LtdZIMLAB · leader · Evidence leans down · 74% evidence42.8out of 100GrowthCapitalValuationRelative
  32. 32Bajaj Healthcare LtdBAJAJHCARE · basing · Evidence leans down · 90% evidence42.7out of 100GrowthCapitalValuationRelative
  33. 33Lincoln Pharmaceuticals LtdLINCOLN · quiet · Evidence leans down · 90% evidence41.5out of 100GrowthCapitalValuationRelative
  34. 34Sun Pharmaceutical Industries LtdSUNPHARMA · quiet · Evidence leans down · 100% evidence39.8out of 100GrowthCapitalValuationRelative
  35. 35RPG Life Sciences LtdRPGLIFE · losing its lead · Evidence leans down · 90% evidence38.9out of 100GrowthCapitalValuationRelative
  36. 36Indoco Remedies LtdINDOCO · turning · Too little evidence to rank firmly · 52% evidence37.8out of 100GrowthCapitalValuationRelative
  37. 37Suven Life Sciences LtdSUVEN · quiet · Most evidence points down · 67% evidence34.4out of 100GrowthCapitalValuationRelative
  38. 38Torrent Pharmaceuticals LtdTORNTPHARM · quiet · Most evidence points down · 100% evidence34.2out of 100GrowthCapitalValuationRelative
  39. 39Natco Pharma LtdNATCOPHARM · quiet · Most evidence points down · 90% evidence31.9out of 100GrowthCapitalValuationRelative
  40. 40Dr Reddys Laboratories LtdDRREDDY · breaking out · Most evidence points down · 100% evidence30.4out of 100GrowthCapitalValuationRelative
  41. 41Cipla LtdCIPLA · quiet · Most evidence points down · 100% evidence27.9out of 100GrowthCapitalValuationRelative
  42. 42Biocon LtdBIOCON · basing · Most evidence points down · 100% evidence22.7out of 100GrowthCapitalValuationRelative
  43. 43Syncom Healthcare LtdSYNCOM · Too little evidence to rank firmly · 17% evidence42.4out of 100GrowthCapitalValuationRelative
  44. 44Sai Parenterals Ltd this pageSAIPARENT · quiet · Too little evidence to rank firmly · 36% evidence38.3out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 17.4/43.75 · Revenue — · Profit — · Operating margin change 0 points · 39% evidenceCapital efficiency 9.9/31.25 · ROCE 5.3% (year to Mar 2026) · Operating margin 20.5% · 76% evidenceValuation 11.0/25 · P/E 93.8× · PEG — · 15% evidenceRelative strength: no reading this week · its 20 points are shared across the other threeExact sum: 17.4 + 9.9 + 11 = 38.3 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose.

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

In this ranking every company's P/E uses its own latest official close and its last four filed quarters, the same rule as the top of this page. ROCE here is each company's last full year, as labelled, so it can differ from the four-quarter ROCE above. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.

Related companies: Pharma - Formulators, all 44 compared on one page.

Which companies are close to Sai Parenterals in size?

Sai Parenterals is the 34th largest of 44 Pharma - Formulators companies on Sector Alpha by market value (at the 18 November 2026 close). Just above it: RPG Life Sciences, Fredun Pharmaceuticals and Indoco Remedies. Just below it: Bharat Parenterals, Amrutanjan Health Care and Accent Microcell.

Pharma - Formulators companies close in size

  1. RPG Life Sciences Ltd ₹4,139 crore
  2. Fredun Pharmaceuticals Ltd ₹2,802 crore
  3. Indoco Remedies Ltd ₹2,234 crore
  4. Sai Parenterals Ltd ₹2,217 crore
  5. Bharat Parenterals Ltd ₹1,682 crore
  6. Amrutanjan Health Care Ltd ₹1,493 crore
  7. Accent Microcell Ltd ₹1,457 crore

All 44 Pharma - Formulators companies, largest first

Companies close in size in other industries

  1. Kilburn Engineering Ltd ₹2,225 crore · Carbon Black
  2. Somany Ceramics Ltd ₹2,222 crore · Ceramics/Tiles/Sanitaryware
  3. Sai Parenterals Ltd ₹2,217 crore
  4. Vintage Coffee & Beverages Ltd ₹2,206 crore · FMCG - Coffee
  5. Thejo Engineering Ltd ₹2,196 crore · Capital Goods - Others

What else do people ask about Sai Parenterals?

What is Sai Parenterals's share price today?

Sai Parenterals Ltd's share price is ₹501.75. The whole company is worth ₹2,216 Cr on the market. In the last 52 weeks it traded between ₹452 to ₹624; today it is 29% of the way up from the low, 1.7% above its 200-day average.

The price has been rising for 31 weeks (as of 18 November 2026).

What were Sai Parenterals's latest quarterly results?

Sai Parenterals Ltd reported revenue of ₹195 Cr and net profit of ₹11.0 Cr for the Sep 2026 quarter. Revenue rose 261.1% and profit rose 83.3% compared with a year earlier. Earnings per share were ₹2.38.

The operating margin was 20.5%, 0.1 percentage points higher than a year earlier (as of 18 November 2026).

What is Sai Parenterals's market cap?

Sai Parenterals Ltd's market capitalisation is ₹2,216 Cr at a share price of ₹501.75. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 18 November 2026).

How is Sai Parenterals performing?

Sai Parenterals Ltd's share price has been rising for 31 weeks. In its latest quarter, revenue rose 261.1% and profit rose 83.3% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 4 weeks running (as of 18 November 2026).

Will Sai Parenterals's share price go up?

This page does not forecast Sai Parenterals Ltd's share price. What it shows instead: the share price is ₹501.75, and it has been rising for 31 weeks. Its P/E of 93.8× is higher than 6% of its own last 1 years (as of 18 November 2026).

Who owns Sai Parenterals?

Promoters own 51.2% of Sai Parenterals Ltd, foreign institutions 2.9%, domestic institutions 7.8% and the public 38.2% (latest quarter). No group of owners changed its stake by a full point over the last two years (as of 18 November 2026).

Does Sai Parenterals have too much debt?

Sai Parenterals Ltd has a moderate amount of debt: its debt is 0.75× its equity, and its operating profit is 2 times its interest bill. At Sep 2026 borrowings were ₹374 Cr against equity of ₹496 Cr.

Keep that borrowing in mind when reading the returns on this page (as of 18 November 2026).

Where is Sai Parenterals in its business cycle?

Sai Parenterals Ltd's FY26 operating margin was 10.2%, against a 4-year range of 10.2% to 23.9%. The latest quarter was 20.5%, near the top of its own range.

Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 18 November 2026).

What could break the Sai Parenterals story?

Biggest thing to watch: the price has already been rising for 31 weeks, so timing is the risk more than the business.

On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 18 November 2026).

Is Sai Parenterals a stock worth studying right now?

What the numbers show: Sai Parenterals Ltd's results are improving, while its P/E is near the low end of its own history over 7 months, higher than only 6% of past readings. The main open question: the next one or two quarters of results.

Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 18 November 2026).

Is there a Sai Parenterals share price forecast for 2026?

What management itself guided: FY27 full-year revenue to very comfortably cross ₹750 crore.

Where do these numbers come from?

Sector Alpha, written by code from the published numbers. Data as of 18 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.

More lists

Every Sector Alpha list, grouped

X · Instagram · YouTube · About · Newsletter · Newsletter archive
This is research, not advice. We’re not SEBI-registered.